SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare moves up on the BSE

06 Apr 2021 Evaluate

Cadila Healthcare is currently trading at Rs. 448.15, up by 8.30 points or 1.89% from its previous closing of Rs. 439.85 on the BSE.

The scrip opened at Rs. 442.10 and has touched a high and low of Rs. 449.85 and Rs. 441.00 respectively. So far 78240 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 290.10 on 07-Apr-2020.

Last one week high and low of the scrip stood at Rs. 449.85 and Rs. 433.25 respectively. The current market cap of the company is Rs. 45751.06 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.96% and 7.97% respectively.

Zydus Cadila has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19.

The treatment regimen would be less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen. It would also ensure better compliance.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

933.30 -5.60 (-0.60%)
11-May-2026 10:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1860.60
Dr. Reddys Lab 1278.75
Cipla 1339.85
Zydus Lifesciences 933.30
Lupin 2252.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×